Sign In
Buy 0YAY
Vitrolife Ab (publ) Earnings Calls
| Release date | Jul 16, 2026 |
| EPS estimate | £0.90 |
| EPS actual | £0.96 |
| EPS Surprise | 7.14% |
| Revenue estimate | 875.71M |
| Revenue actual | 857M |
| Revenue Surprise | -2.14% |
| Release date | Apr 23, 2026 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | 824.084M |
| Revenue actual | - |
| Release date | Feb 03, 2026 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | 903.267M |
| Revenue actual | - |
| Release date | Apr 18, 2024 |
| EPS estimate | - |
| EPS actual | £0.85 |
| Revenue estimate | - |
| Revenue actual | 841M |
Last 4 Quarters for Vitrolife Ab (publ)
Below you can see how 0YAY.L performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Apr 18, 2024 |
| Price on release | £167.05 |
| EPS estimate | - |
| EPS actual | £0.85 |
| Date | Price |
|---|---|
| Apr 12, 2024 | £193.20 |
| Apr 15, 2024 | £191.45 |
| Apr 16, 2024 | £185.45 |
| Apr 17, 2024 | £181.85 |
| Apr 18, 2024 | £167.05 |
| Apr 19, 2024 | £166.00 |
| Apr 22, 2024 | £164.40 |
| Apr 23, 2024 | £165.25 |
| Apr 24, 2024 | £161.25 |
| 4 days before | -13.54% |
| 4 days after | -3.47% |
| On release day | 0% |
| Change in period | -16.54% |
| Release date | Feb 03, 2026 |
| Price on release | £92.83 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Jan 28, 2026 | £120.40 |
| Jan 29, 2026 | £118.00 |
| Jan 30, 2026 | £117.45 |
| Feb 02, 2026 | £117.55 |
| Feb 03, 2026 | £92.83 |
| Feb 04, 2026 | £89.40 |
| Feb 05, 2026 | £90.58 |
| Feb 06, 2026 | £89.58 |
| Feb 09, 2026 | £88.73 |
| 4 days before | -22.90% |
| 4 days after | -4.42% |
| On release day | -3.69% |
| Change in period | -26.31% |
| Release date | Apr 23, 2026 |
| Price on release | £119.25 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 17, 2026 | £109.45 |
| Apr 20, 2026 | £109.35 |
| Apr 21, 2026 | £108.80 |
| Apr 22, 2026 | £107.55 |
| Apr 23, 2026 | £119.25 |
| Apr 24, 2026 | £115.05 |
| Apr 27, 2026 | £113.25 |
| Apr 28, 2026 | £110.10 |
| Apr 29, 2026 | £104.98 |
| 4 days before | 8.95% |
| 4 days after | -11.97% |
| On release day | -3.52% |
| Change in period | -4.09% |
| Release date | Jul 16, 2026 |
| Price on release | £96.43 |
| EPS estimate | £0.90 |
| EPS actual | £0.96 |
| EPS surprise | 7.14% |
| Date | Price |
|---|---|
| Jul 10, 2026 | £88.45 |
| Jul 13, 2026 | £87.88 |
| Jul 14, 2026 | £87.30 |
| Jul 15, 2026 | £87.53 |
| Jul 16, 2026 | £96.43 |
| Jul 17, 2026 | £92.20 |
| Jul 20, 2026 | £90.45 |
| Jul 21, 2026 | £87.88 |
| Jul 22, 2026 | £89.78 |
| 4 days before | 9.02% |
| 4 days after | -6.90% |
| On release day | -4.38% |
| Change in period | 1.50% |
Vitrolife Ab (publ) Earnings Call Transcript Summary of Q2 2026
Vitrolife reported Q2 2026 results with SEK 857m net sales (1% organic growth, -2% in SEK due to exited businesses and minor FX headwind), a strong gross margin of 60.3% (+~2 p.p. y/y), EBITDA SEK 295m (34.4% margin) and net income SEK 129m (EPS SEK 0.95). Key commercial highlights: very strong Consumables performance in the Americas (record Consumables revenue SEK 358m; 15% organic growth driven by media wins) and continued EmbryoScope penetration and utilization. The company launched EmbryoCath and EmbryoViewer Pro (new embryo transfer and advanced time‑lapse software). Regionally: EMEA +1% organic (Middle East materially down due to geopolitical disruption), Americas +1% organic (North America strong; South America showing exits of low‑profit genetics accounts), APAC -1% organic (China cycles declining; Japan and SE Asia stronger). Management emphasized a strategic focus on profitable growth, exiting low‑margin genetics tests/accounts (NACE and GPDx fully exited) and markets, improving gross margins via portfolio mix and operational efficiency, and continued investment in prioritized markets and R&D. CFO noted cost reductions (OpEx down SEK 48m y/y), one‑time positive items, working capital build-up reducing cash flow vs prior year, net debt/EBITDA 0.7x, and a new share repurchase program up to SEK 500m to optimize capital structure alongside the existing dividend policy. The company reiterated the move from volume/market-share chasing in low‑margin segments toward a premium, profitability‑first approach amid softer IVF cycle trends in certain regions (notably China and the Middle East).
